MitoQ improves vascular function in healthy older adults (Rossman et al., 2018)
Human RCT — functional endpoint
Record verify: source publication identified; see evidence and limitations
| Design | Randomized, double-blind, placebo-controlled crossover trial (functional/vascular) |
| N | 24 |
| Registry | NCT02597023 |
| PMID | 29661838 |
| DOI | 10.1161/HYPERTENSIONAHA.117.10787 |
| Citation status | Original publication identity matched by title, author and DOI; relevant full-text sections, results and limitations examined 2026-10-14. The trial identifier is reported in the original source. |
Identifiers: DOI verified; PMC verified; PMID verified; trial registry id reported, not independently verified. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | 24 healthy adults aged 60–79 years with impaired endothelial function were randomized; 20 completed both six-week crossover periods. |
| Exposure, route, schedule | Oral MitoQ 20 mg/day for 6 weeks. |
| Comparator / duration | Placebo-controlled, double-blind, randomized crossover. |
| Endpoint / numeric result | Brachial-artery flow-mediated dilation ~42% higher after MitoQ vs placebo; lower aortic stiffness (in those with elevated baseline) and lower plasma oxidised LDL. |
| What it did NOT establish | The primary functional endpoint was brachial-artery flow-mediated dilation, with a sample-size calculation targeting that measure. This small six-week crossover trial does not establish reduced clinical events, mortality or longer lifespan. The stiffness result was restricted to the elevated-baseline subgroup; mitochondrial ROS was not directly measured in this trial. Observed short-term tolerability does not establish broader or long-term safety. |
Interventions
Related retailer search
These links open retailer searches for related supplement brands. They do not verify the brand, formulation or dose used in this individual trial, or the contents of any current listing. The study doses and outcomes are reported in the record above. No personal dose is recommended.
- MitoQ (mitoquinone)
Find MitoQ (mitoquinone) on Amazon →
Links marked with an arrow are affiliate links: MitoiX may earn a commission from qualifying purchases. Retailers determine prices and purchase terms. This never affects what is published — see the affiliate disclosure.
Primary reference
https://doi.org/10.1161/HYPERTENSIONAHA.117.10787
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.